Suppr超能文献

发展中国家轮状病毒免疫经济评价:文献综述。

Economic evaluations of rotavirus immunization for developing countries: a review of the literature.

机构信息

Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.

出版信息

Expert Rev Vaccines. 2011 Jul;10(7):1037-51. doi: 10.1586/erv.11.65.

Abstract

Diarrhea is a leading cause of mortality for children under 5 years of age, and rotavirus is identified as the main cause of severe diarrhea worldwide. Since 2006, two rotavirus vaccines, Rotarix and Rotateq, have been available in the market. These vaccines have proved to have high efficacy in developed countries. Clinical trials are being undertaken in Asia and Africa, and early clinical results found that the vaccine significantly reduces severe diarrhea episodes due to rotavirus (48.3% for Asia and 30.2% for Africa). The WHO recommended that rotavirus immunization be included in all national immunization programs. Based on WHO's recommendations, the Global Alliance for Vaccines and Immunization decided to provide financial support for rotavirus immunization in the developing world. In this article, we attempted to ascertain the cost-effectiveness of universal rotavirus immunization in developing countries. After an extensive literature search, we identified and evaluated 15 cost-effectiveness studies conducted in the developing world. The results from these studies showed that rotavirus immunization is a cost-effective strategy and one of the best interventions to prevent rotavirus-related diarrheal disease. However, rotavirus vaccines are expensive and the vaccine price appears to be the most challenging and crucial factor for decision-makers regarding whether to introduce this vaccine into developing countries' immunization schedules. All the studies concluded that rotavirus immunization is cost effective but may not be affordable for the developing world at present. Developing countries will definitely rely on financial support from international organizations to introduce rotavirus vaccination. It is recommended that more research on cost-effective rotavirus immunization with updated data be conducted and new rotavirus vaccine candidates be developed at a cheaper price to speed up the introduction of rotavirus immunization to the developing world.

摘要

腹泻是导致 5 岁以下儿童死亡的主要原因,轮状病毒被认为是导致全球严重腹泻的主要原因。自 2006 年以来,两种轮状病毒疫苗,Rotarix 和 Rotateq,已经在市场上销售。这些疫苗已被证明在发达国家具有很高的功效。亚洲和非洲正在进行临床试验,早期临床结果发现该疫苗显著降低了轮状病毒引起的严重腹泻发作(亚洲为 48.3%,非洲为 30.2%)。世界卫生组织建议将轮状病毒免疫纳入所有国家免疫规划。根据世界卫生组织的建议,全球疫苗和免疫联盟决定为发展中国家的轮状病毒免疫提供财政支持。在本文中,我们试图确定在发展中国家普遍进行轮状病毒免疫的成本效益。经过广泛的文献检索,我们确定并评估了在发展中国家进行的 15 项成本效益研究。这些研究的结果表明,轮状病毒免疫是一种具有成本效益的策略,也是预防轮状病毒相关腹泻病的最佳干预措施之一。然而,轮状病毒疫苗价格昂贵,对于决策者来说,疫苗价格似乎是决定是否将该疫苗纳入发展中国家免疫计划的最具挑战性和关键的因素。所有研究都表明,轮状病毒免疫具有成本效益,但目前对发展中国家来说可能负担不起。发展中国家肯定需要依靠国际组织的财政支持来引入轮状病毒疫苗接种。建议对具有更新数据的具有成本效益的轮状病毒免疫进行更多研究,并开发更便宜的新轮状病毒候选疫苗,以加快在发展中国家引入轮状病毒免疫。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验